OBIO Member: Focal Healthcare Inc Receives Health Canada Approval

Ontario Industry Updates
Written By obio

 

OBIO Member, Focal Healthcare Inc, has been granted a Class II Health Canada Medical Device License for its targeted prostate biopsy device, Fusion Bx. Fusion Bx uses MRI/Ultrasound fusion to provide urologists with 3D image-guidance, allowing biopsies to be taken directly from suspicious cancer regions in the prostate for improved prostate cancer diagnosis. 

Click HERE to read the full press release

obio
Previous

OBIO Partner: StarFish Medical's 2nd Annual Digital Health Survey
Next

CAAP Company: Swift Medical Closes Over Subscribed Funding Round